BOLT Stock Analysis: Buy, Sell, or Hold?
BOLT - Bolt Biotherapeutics, Inc. Common Stock
$3.83
0.02 (0.52%)
▲
5d:
-13.35%
30d:
-9.24%
90d:
-19.71%
WAIT
LOW Confidence
Analysis Updated: Jul 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
16d
Get Alerted When BOLT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BOLT is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BOLT is down 13.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BOLT is currently trading at $3.83, which is considered oversold relative to its 30-day fair value range of $3.88 to $4.24.
Technical Outlook: Technically, BOLT is in a downtrend. The price is currently testing key support at $3.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BOLT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $41.00 (+970.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BOLT is in a downtrend. The price is currently testing key support at $3.78. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BOLT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $41.00 (+970.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.88 -
$4.24
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 970.5% below Wall St target ($41.00)
- WARNING: Recommendation downgraded due to -13.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.88 -
$4.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.78
Resistance Level
$4.50
Current Trend
Downtrend
Technical data as of
Jul 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.02
Wall Street Target
$41.00
(+970.5%)
Revenue Growth (YoY)
-97.9%
Share & Embed Analysis
Last updated: July 27, 2026 12:00 AM ET
Data refreshes hourly during market hours. Next update: 1:00 AM
Data refreshes hourly during market hours. Next update: 1:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BOLT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$86 | 59 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1079 | 53 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
